Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

1000 patients have been recruited for the Pearl study within the DeLIVER programme.

As of this week, we are delighted to announce that 1000 patients have been recruited to the Pearl study from 40 hospital sites across the UK, a great milestone for this study. We’d like to give huge thanks to each hospital site involved in Pearl, your hard work on the study is much appreciated.

The Pearl (Prospective Cohort for Early Detection of Liver cancer) clinical study has been developed to recruit patients with cirrhosis who are known to be at high risk for liver cancer. The Pearl study is a key clinical study in the CRUK funded DeLIVER programme that aims to use new technologies for liver cancer risk prediction and detection. Patients in the Pearl study may have liver cancer caused by hepatitis virus B or C, alcohol or obesity. These participants show a higher risk of developing liver cancer and will be monitored over time to identify the earliest detectable indications of liver cancer and to develop new prediction models for the individual risk of liver cancer development. A proportion of participants have already been diagnosed with HCC since enrolment to the study providing invaluable data and samples.

The Cancer Research UK funded DeLIVER programme led by Ludwig Oxford's Professor Eleanor Barnes aims to overcome the barriers to the early detection of Hepatocellular cancer (HCC) by characterising the pre-cancerous liver microenvironment and measuring this by applying new methodologies in a range of disciplines. By establishing an internationally renowned research team with expertise in the fields of immunology, imaging, (epi)genomics, biochemistry, oncology and integrative data science, the DeLIVER programme looks to target the early detection of HCC and improve patient survival.

Read more about the DeLIVER programme and the team organising the Pearl clinical study by visiting the DeLIVER website.

Pearl Recruiting Sites

Aintree

Basingstoke

Birmingham

Bournemouth

Bradford

Brighton

Bristol

Burton

Chelsea & Westminster

Cornwall

County Durham & Darlington

Derby

Devon

East Kent

Gateshead

Gloucester

Guy’s and St Thomas'

Hull

Imperial

King’s

Leeds

Leicester

Liverpool

Manchester

Middlesbrough

Milton Keynes

Newcastle

Norfolk & Norwich

Nottingham

Oxford

Plymouth

Portsmouth

Royal Free

Royal London

Sheffield

Southampton

St George's

West Middlesex

Weston

Wycombe